for people ages 18 years and up (full criteria)
at La Jolla, California and other locations
study started
estimated completion:



Prospective, interventional multicenter study evaluating adoptive cell therapy (ACT) with Lifileucel infusion (LN-144) followed by interleukin 2 (IL-2) after a nonmyeloablative lymphodepletion (NMA-LD) preparative regimen.

Official Title

A Phase 2, Multicenter Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Treatment of Patients With Metastatic Melanoma


Lifileucel is an autologous adoptive cell transfer therapy that utilizes a TIL manufacturing process, as originally developed by the NCI, for the treatment of patients with metastatic melanoma. The adoptive cell transfer therapy used in this study involves patients receiving a lymphocyte depleting preconditioning regimen, prior to infusion of autologous TIL, followed by the administration of a regimen of IL-2.


Metastatic Melanoma Autologous Adoptive Cell Transfer Autologous Adoptive Cell Therapy Cellular Immuno-therapy Cell Therapy Tumor Infiltrating Lymphocytes TIL LN-144 IL-2 Melanoma Lifileucel


For people ages 18 years and up

Main Criteria for Inclusion:

  1. Patients with unresectable or metastatic melanoma (Stage IIIc or Stage IV) who progressed following ≥ 1 lines of prior systemic therapy, including immune checkpoint inhibitor (eg, anti-PD-1), and if BRAF mutation-positive, after BRAF inhibitor systemic therapy. Patients must have no other therapy options that are expected to have significant benefit in the opinion of the Investigator and must have:
  2. At least 1 measurable target lesion, as defined by RECIST 1.1. Lesions in previously irradiated areas should not be selected as target lesion, unless treatment was ≥ 3 months prior, and there has been demonstrated disease progression in the lesion
  3. At least 1 resectable target lesion to generate TIL of a minimum 1.5 cm in diameter post-resection; surgical removal with minimal morbidity (defined as any procedure for which expected hospitalization is ≤ 3 days)
  4. Patients must be ≥18 years and ≤70 years of age at the time of consent. Enrollment of patients >70 years of age may be allowed after consultation with the Medical Monitor
  5. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and an estimated life expectancy of ≥ 3 months
  6. In the opinion of the Investigator, patient must be able to complete all study-required procedures
  7. Patients of childbearing potential or their partners of childbearing potential must be willing to practice an approved method of birth control during treatment and for 12 months after receiving last protocol-related therapy

Approved methods of birth control are as follows:

  • Combined (estrogen and progestogen containing) hormonal birth control associated with inhibition of ovulation: oral; intravaginal; transdermal
  • Progestogen-only hormonal birth control associated with inhibition of ovulation:oral; injectable; implantable
  • Intrauterine device (IUD)
  • Intrauterine hormone-releasing system (IUS)
  • Bilateral tubal occlusion
  • Vasectomized partner
  • True sexual abstinence when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (eg, calendar ovulation,symptothermal, post-ovulation methods) is not acceptable.
  • Patients must have the following hematologic parameters:
  • Absolute neutrophil count (ANC) ≥ 1000/mm3
  • Hemoglobin ≥ 9.0 g/dL
  • Platelet count ≥ 100,000/mm3
  • Patients must have adequate organ function:
  • Serum alanine transaminase (ALT)/ serum glutamic-pyruvic transaminase (SGPT) and aspartate transaminase (AST)/serum glutamic oxaloacetic transaminase (SGOT) ≤ 3 times the upper limit of normal [ULN]), patients with liver metastasis ≤ 5 times ULN
  • An estimated creatinine clearance (eClCr) ≥ 40 mL/min using the Cockcroft Gault formula at Screening
  • Total bilirubin ≤ 2 mg/dL: Patients with Gilbert's syndrome must have a total bilirubin ≤ 3 mg/dL
  • Patients must be seronegative for the human immunodeficiency virus (HIV) antibody,hepatitis B antigens, and hepatitis C antibody or antigen
  • Patients must have recovered from all prior therapy-related adverse events (AEs) to ≤Grade 1 (per Common Terminology Criteria for Adverse Events [CTCAE] v4.03), except for alopecia or vitiligo, prior to enrollment (tumor resection), with a washout period from prior anticancer therapy(ies) to the start of planned NMA-LD of a minimum duration detailed as follows:
  • Targeted therapy: prior targeted therapy with a MEK/BRAF or other-directed agent,is allowed provided the washout period is a ≥ 21 days or 5 half-lives, whichever is longer prior to the start of NMA-LD
  • Chemotherapy: adjuvant, neoadjuvant or definitive chemotherapy/ chemoradiation is allowed provided the washout period is ≥ 21 days or 5 half-lives, whichever is longer prior to the start of NMA-LD
  • Immunotherapy: prior checkpoint-targeted therapy with an anti-CTLA-4/anti-PD-1,other monoclonal antibody (mAb), or vaccine is allowed if disease progression is confirmed prior to or within the washout period of ≥ 21 days before the start of NMA-LD
  • Palliative radiation therapy is permitted between biopsy and NMA-LD if it does not involve lesions being selected as target or nontarget
  • Patients may undergo preplanned procedures if within 2 to 3 weeks prior to the start of NMA-LD
  • . Patients with documented Grade 2 or higher diarrhea or colitis as a result of previous treatment with immune checkpoint inhibitor(s) must have been asymptomatic for at least 6 months and/or had a normal colonoscopy post immune checkpoint inhibitor treatment by visual assessment, prior to start of NMA-LD
  • . Patients must have the ability to understand the requirements of the study, have provided written informed consent, as evidenced by signature on an informed consent form (ICF) approved by an Institutional Review Board/Independent Ethics Committee(IRB/IEC), and agree to abide by the study restrictions and return to the site for the required assessments
  • . Patients have provided written authorization for use and disclosure of protected health information

Criteria for Exclusion:

  1. Patients with melanoma of uveal/ocular origin
  2. Patients who have received an organ allograft or prior cell transfer therapy that included a nonmyeloablative or myeloablative chemotherapy regimen (not applicable for patients in the retreatment Cohort 3)
  3. Patients with symptomatic and/or untreated brain metastases (of any size and any number)
  4. Patients with definitively treated brain metastases may be considered for enrollment after discussion with the Medical Monitor, and must be stable for ≥ 2 weeks prior to the start of NMA-LD
  5. Patients who are pregnant or breastfeeding
  6. Patients who are on a systemic steroid therapy at a dose of > 10 mg of prednisone or equivalent per day
  7. A short course of higher-dose steroid therapy is allowed in cases of exacerbation of known disease or for treatments of new acute symptoms
  8. Patients who have active medical illness(es) that in the opinion of the Investigator would pose increased risk for study participation that may include active systemic infections, such as syphilis, or any other infections requiring antibiotics,coagulation disorders, or other active major medical illnesses of the cardiovascular,respiratory, or immune system
  9. Patients who have any form of primary immunodeficiency (such as severe combined immunodeficiency disease [SCID] or acquired immunodeficiency syndrome [AIDS])
  10. Patients who have a history of hypersensitivity to any component or excipient of the

TIL therapy and other study drugs:

  • NMA-LD (cyclophosphamide, mesna, and fludarabine)
  • IL-2
  • Antibiotics of the aminoglycoside group (ie, streptomycin, gentamicin)
  • Any component of the TIL infusion product formulation including dimethyl sulfoxide [DMSO], human serum albumin [HSA], IL-2, and dextran-40
  • Patients who have a left ventricular ejection fraction (LVEF) < 45% or New York Heart Association (NYHA) functional classification > Class 1 at Screening. All patients must have echocardiogram (ECHO) or multiple gated acquisition scan (MUGA) at Screening. For patients ≥ 60 years or patients who have a history of ischemic heart disease, chest pain, or clinically significant atrial and/or ventricular arrhythmias, a cardiac stress tests must be performed showing LVEF ≥45%, and if any wall movement abnormalities, they must be reversible.
  • . Patients who have obstructive or restrictive pulmonary disease and have a documented FEV1 (forced expiratory volume in 1 second) of ≤ 60%
  • . Patients who have had another primary malignancy within the previous 3 years (with the exception of carcinoma in situ of the breast, cervix, or bladder, localized prostate cancer and nonmelanoma skin cancer that has been adequately treated)
  • . Patients who have been shown to be BRAF mutation positive (V600), but have not received prior systemic therapy with a BRAF-directed kinase inhibitor
  • . Patients who have received a live or attenuated vaccine within 28 days of the start of NMA-LD
  • . Patients whose cancer requires immediate attention or who would otherwise suffer a disadvantage by participating in this trial
  • . Patients protected by the following constraints:
  • Hospitalized persons without consent or persons deprived of liberty because of a judiciary or administrative decision
  • Adult persons with a legal protection measure or persons who cannot express their consent
  • Patients in emergency situations who cannot consent to participate in the trial


  • University of California San Diego Moores Cancer Center
    La Jolla California 92093 United States
  • The Angeles Clinic and Research Institute
    Los Angeles California 90048 United States


in progress, not accepting new patients
Start Date
Completion Date
Iovance Biotherapeutics, Inc.
Phase 2
Study Type
Last Updated